IL-13 is a driver of COVID-19 severity

Mostrar otras versiones (1)

Immune dysregulation is characteristic of the more severe stages of SARS-CoV-2 infection. Understanding the mechanisms by which the immune system contributes to COVID-19 severity may open new avenues to treatment. Here we report that elevated interleukin-13 (IL-13) was associated with the need for m...

Descripción completa

Detalles Bibliográficos
Autores principales: Donlan, Alexandra N., Sutherland, Tara E., Marie, Chelsea, Preissner, Saskia, Bradley, Ben T., Carpenter, Rebecca M., Sturek, Jeffrey M., Ma, Jennie Z., Moreau, G. Brett, Donowitz, Jeffrey R., Buck, Gregory A., Serrano, Myrna G., Burgess, Stacey L., Abhyankar, Mayuresh M., Mura, Cameron, Bourne, Philip E., Preissner, Robert, Young, Mary K., Lyons, Genevieve R., Loomba, Johanna J., Ratcliffe, Sarah J, Poulter, Melinda D., Mathers, Amy J., Day, Anthony, Mann, Barbara J., Allen, Judith E., Petri, William A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cold Spring Harbor Laboratory 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7941663/
https://www.ncbi.nlm.nih.gov/pubmed/33688686
http://dx.doi.org/10.1101/2020.06.18.20134353

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7941663/
https://www.ncbi.nlm.nih.gov/pubmed/33688686
http://dx.doi.org/10.1101/2020.06.18.20134353

Ejemplares similares